Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Alize Pharma raises funds to advance AZP-531

June 7, 2012

Long-term study of Contrave begins enrollment

June 7, 2012

U.S. team presents new products for cancer and other disorders

June 7, 2012

Phase III elagolix study begins in endometriosis

June 6, 2012

CHMP schedules hearing for Vivus' Qnexa MAA

June 6, 2012

Janssen files NDA for canagliflozin

June 5, 2012

Takeda expands its position in gout market

June 5, 2012

Mitsubishi Tanabe terminates license agreement

June 4, 2012

Roche group identifies new cathepsin inhibitors

June 4, 2012

U.S. team patents new DAP kinase 1 inhibitors and PPAR-gamma/GPR120 partial agonists

June 1, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...